This includes: adopting the broadest lists of preventive prescription drugs that are either fully covered or covered at a discount, lower premiums and deductibles, and increased Health Savings Account contributions for lower-income consumers based on IRS income requirements
coli and used to immunize mice
For semaglutide, the earliest realistic timeline for generic injectable entry: 2029: Generic manufacturers begin bioequivalence studies (2 years before the 2031 method-of-use patent expiration) 2030: ANDA submissions filed 2031-2032: FDA approvals granted, market entry Generic oral semaglutide could follow a faster timeline because Teva's Paragraph IV strategy (using a different absorption enhancer) avoids the SNAC patent entirely: 2026: Teva completes bioequivalence studies (already done as of April 2026) 2026: ANDA submission 2027: FDA approval, market entry The gap between patent expiration and market entry is why patients should not expect immediate cost relief when patents expire
Accessed 17 Mar 2024 Nickel KF, Long AT, Fuchs TA et al (2017) Factor XII as a therapeutic target in thromboembolic and inflammatory diseases
Participants with a diagnosis of type 1 or 2 diabetes, chronic pancreatitis, uncontrolled thyroid disease, or with a history of recent cardiovascular events were excluded from the trial
5,11 Figure 1: GLP-1 Timeline